Amgen projects 2026 revenue of $38.9B-$39.7B while raising non-GAAP EPS to $22.90-$23.70 (NASDAQ:AMGN)
Amgen (AMGN) reported Q3 2026 revenues of $10.4B, up 8% YoY. Management projects 2026 revenue of $38.9B-$39.7B and non-GAAP EPS of $22.90-$23.70. Key growth drivers grew 27% YoY, representing over 70% of total revenue.
How this was made
The 30-second read
Why it matters
New 2026 revenue and non-GAAP EPS ranges are the key tradable inputs, affecting analyst model updates and positioning for the next earnings cycle.
Market read
Traders can update 2026 estimate expectations and reassess valuation multiples based on the explicit guidance ranges.
What to watch
Non-GAAP guidance can mask underlying margin or amortization dynamics; traders may focus on reconciliation items, product mix, and whether the 6 growth drivers are tied to specific launches or cycle timing not shown in the excerpt.
Background
The piece is an automated earnings-call summary for Amgen’s Q3 2026, highlighting management commentary and forward-looking targets.
Ticker impact
Amgen guides 2026 revenue to $38.9B-$39.7B and raises non-GAAP EPS to $22.90-$23.70, setting a new earnings benchmark.
Likely upward bias if the market views the 2026 revenue and non-GAAP EPS range as credible and above expectations, with volatility around the midpoint.
The article’s headline and quoted management framing provide explicit forward guidance ranges, which typically drive revisions to estimates and multiples. However, the body excerpt is truncated and does not include consensus comparisons or additional drivers.
Market effects
Large-cap biotech earnings guidance can influence sentiment for peers with similar growth-driver narratives and non-GAAP reporting.
Primarily impacts US large-cap biotech sentiment and index constituents via AMGN’s weight.
Limited direct global spillover beyond biotech risk appetite, unless guidance signals broader demand or pipeline strength.
Counterpoint
If the guidance is largely a re-baseline of already-expected growth, the stock reaction may be muted or negative due to valuation already pricing in improvement.
Key entities
- companyAmgen
US-listed biotech issuer providing 2026 revenue and non-GAAP EPS guidance ranges.
- personRobert Bradway
Amgen chairman and CEO quoted on quarterly revenue growth and growth drivers.
